Literature DB >> 24288522

The Neuropsychopharmacology of Pathological Gambling.

Kourosh Zakeri1, Marc N Potenza.   

Abstract

Pathological gambling (PG) is an impulse control disorder with prevalence estimates in the range of 0.2-2% in the general population. PG can significantly impact one's ability to function as it may negatively influence social, financial, and occupational aspects of life. Historically, PG has received relatively little attention from researchers and clinicians, and few treatments, particularly pharmacological, have been both validated and widely employed. Given the clinical relevance of PG, it is important that researchers examine pharmacological and behavioral treatments for their safety and efficacy and that clinicians use empirically validated therapies. Multiple neurochemicals, including serotonin, dopamine, norepinephrine, and opioids, and related neurocircuitry, particularly ventral cortico-striatal pathways, have been implicated in PG. The neurobiological rationale for therapies, particularly pharmacological ones, is reviewed with a perspective on the generation of improved prevention and treatment strategies for PG.

Entities:  

Keywords:  Addiction; functional magnetic resonance imaging; gambling; impulse control disorder

Year:  2012        PMID: 24288522      PMCID: PMC3840429          DOI: 10.2174/157340012798994911

Source DB:  PubMed          Journal:  Curr Psychiatry Rev        ISSN: 1573-4005


  66 in total

1.  A twin study of the association between pathological gambling and antisocial personality disorder.

Authors:  W S Slutske; S Eisen; H Xian; W R True; M J Lyons; J Goldberg; M Tsuang
Journal:  J Abnorm Psychol       Date:  2001-05

2.  Serotonin 1B receptor imaging in pathological gambling.

Authors:  Marc N Potenza; Espen Walderhaug; Shannan Henry; Jean-Dominique Gallezot; Beata Planeta-Wilson; Jim Ropchan; Alexander Neumeister
Journal:  World J Biol Psychiatry       Date:  2011-09-22       Impact factor: 4.132

3.  Neuroendocrine response to casino gambling in problem gamblers.

Authors:  Gerhard Meyer; Jan Schwertfeger; Michael S Exton; Onno E Janssen; Wolfram Knapp; Michael A Stadler; Manfred Schedlowski; Tillmann H C Krüger
Journal:  Psychoneuroendocrinology       Date:  2004-11       Impact factor: 4.905

4.  Retaining pathological gamblers in cognitive behavior therapy through motivational enhancement: A pilot study.

Authors:  Edelgard Wulfert; Edward B Blanchard; Brian M Freidenberg; Rebecca S Martell
Journal:  Behav Modif       Date:  2006-05

5.  Predicting response to opiate antagonists and placebo in the treatment of pathological gambling.

Authors:  Jon E Grant; Suck Won Kim; Eric Hollander; Marc N Potenza
Journal:  Psychopharmacology (Berl)       Date:  2008-06-26       Impact factor: 4.530

6.  Pathological gambling. A psychobiological study.

Authors:  A Roy; B Adinoff; L Roehrich; D Lamparski; R Custer; V Lorenz; M Barbaccia; A Guidotti; E Costa; M Linnoila
Journal:  Arch Gen Psychiatry       Date:  1988-04

Review 7.  Molecular mechanisms of drug reinforcement and addiction.

Authors:  D W Self; E J Nestler
Journal:  Annu Rev Neurosci       Date:  1995       Impact factor: 12.449

8.  Prevalence of repetitive and reward-seeking behaviors in Parkinson disease.

Authors:  V Voon; K Hassan; M Zurowski; M de Souza; T Thomsen; S Fox; A E Lang; J Miyasaki
Journal:  Neurology       Date:  2006-09-06       Impact factor: 9.910

9.  Effects of the atypical stimulant modafinil on a brief gambling episode in pathological gamblers with high vs. low impulsivity.

Authors:  M Zack; C X Poulos
Journal:  J Psychopharmacol       Date:  2008-06-26       Impact factor: 4.153

10.  Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study.

Authors:  Donald W Black; Stephan Arndt; William H Coryell; Tami Argo; Kelsie T Forbush; Martha C Shaw; Paul Perry; Jeff Allen
Journal:  J Clin Psychopharmacol       Date:  2007-04       Impact factor: 3.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.